{"id":"W1933865299","doi":"10.1158/1538-7445.sabcs14-s6-03","title":"Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"York University","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Metastatic breast cancer; Cancer; Breast cancer; Oncology; Estrogen receptor; Bortezomib; Clinical endpoint; Progression-free survival; Randomized controlled trial; Chemotherapy; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001927161,0.00204218,0.002643367,0.0004556413,0.0004621974,0.001194381,0.001230212,0.002025472,0.01413701],"category_scores_gemma":[0.001317804,0.0006527565,0.001776107,0.0004844181,0.00136675,0.001164319,0.0004597884,0.003463463,0.002323146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001108005,"about_ca_system_score_gemma":0.001760913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001772867,"about_ca_topic_score_gemma":0.004662506,"domain_scores_codex":[0.9995272,0.0002515657,0.00002584613,0.00008040361,0.00003763887,0.00007735068],"domain_scores_gemma":[0.999184,0.000147178,0.0001543901,0.00006171364,0.00005533953,0.0003974219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9826655,0.003786528,0.0004576746,0.0003694019,0.0004065223,0.00003888009,0.00004110466,0.0002848482,0.002364362,0.0001194763,0.001826611,0.00763906],"study_design_scores_gemma":[0.9736138,0.0246961,0.0006666274,0.00001443426,0.0001145275,0.00001942714,0.000009993934,0.0002054062,0.0001421588,0.00007479698,0.000436058,0.000006579834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762887,0.004016681,0.0005349612,0.00217986,0.0008627691,0.007620598,0.003906955,0.0002478662,0.004341786],"genre_scores_gemma":[0.9643068,0.002809807,0.001921906,0.002740209,0.0007665339,0.010726,0.004862923,0.00007024772,0.01179554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01413701,"threshold_uncertainty_score":0.04729295,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09604018843932562,"score_gpt":0.4197523491040481,"score_spread":0.3237121606647225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}